| According
to the new IMS
World Review, in 2002, global audited sales
of pharmaceuticals rose 8% (at a constant dollar rate) to
reach $400.6 billion.
IMS
World Review tracks actual sales of approximately 90% of
all prescription drugs and certain over-the-counter (OTC)
products in more than 70 countries. Proprietary data projection
methodologies are then used to estimate total global pharmaceutical
sales, which grew to $430.3 billion in 2002.
"Despite
economic challenges in the world's leading markets and a
lower-than-normal number of new product introductions, the
global pharmaceutical industry experienced solid growth
in 2002," said Graham Lewis, IMS Vice President, Strategic
Global Solutions. "Generic drug sales strengthened
in North America and Western Europe due to several patent
expiries, while the Japan market continued to show nearly
flat growth. Aging populations and the ongoing demand for
innovative therapies are expected to effectively sustain
pharmaceutical growth in 2003 and beyond."
As sales
in Latin America slumped 10% due to the economic problems
there, North America, Europe and Japan cemented their position:
in total these regions accounted for 88% of audited worldwide
pharmaceutical sales in 2002. North America was yet again
the strongest performer, growing 12% at a constant dollar
rate to reach $203.6 billion - 51% of the world's total.
Europe grew 8-9%, and Japan, the second-largest individual
market, recorded 1% growth. The rest of Asia, Africa and
Australia combined showed a healthy increase of 11%.
2002
Global pharma sales by region
| World
Audited Market |
2002
Sales ($bn) |
%
Global sales ($) |
%
Growth (constant $) |
|
North
America |
203.6 |
51% |
+12% |
|
European
Union |
90.6 |
22 |
+8 |
|
Rest
of Europe |
11.3 |
3 |
+9 |
|
Japan
|
46.9 |
12 |
+1 |
|
Asia,
Africa and Australia |
31.6 |
8 |
+11 |
|
Latin
America |
16.5 |
4 |
-10 |
|
|
|
|
|
|
TOTAL
|
$400.6bn |
100.0% |
+8% |
Source:
IMS World Review 2003. Sales cover direct and indirect pharmaceutical
channel purchases in US dollars from pharmaceutical wholesalers
and manufacturers. The figures above represent 52 weeks of
sales data, and include prescription and certain OTC data
and represent manufacturer prices.
Leading
therapy classes
Showing little change from 2001, the top ten therapy classes
accounted for 31% of the total audited world market in 2002.
Antiulcerants
were again the largest class, but this situation may change
in 2003 given the generic competition for market leader
Prilosec/Losec (omeprazole), from AstraZeneca,
now present in the United States.
Cholesterol
& triglyceride reducers were a close second, and could
surpass ulcer drugs thanks to the continuing strong performance
of Pfizer's Lipitor (atorvastatin), which
eclipsed Prilosec as the top selling individual product
in 2001, and the imminent arrival of Shionogi and AstraZeneca's
'superstatin' Crestor (rosuvastatin).
Perhaps
reflecting the loss
of exclusivity and new OTC status for Schering-Plough's
blockbuster Claritin (loratadine) in the
USA, the systemic antihistamine class dropped out of the
top 10 in 2002, to be replaced by the erythropoietins -
which came straight in at number seven. This class is dominated
by products such as Epogen, Aranesp
and Erypo/Procrit, from Amgen and its licensee
Johnson & Johnson.
Just
ahead of the EPOs, the strongest growth, of 19%, again came
from antipsychotics, led by Eli Lilly's Zyprexa
(olanzapine) and J&J's Risperdal (risperidone),
and now also including Abilify (aripiprazole),
the new schizophrenia therapy from Otsuka and Bristol-Myers
Squibb.
Leading
therapy classes in 2002 global pharmaceutical sales*
| Rank |
Audited
World Therapy Class |
2002
Sales ($bn) |
%
Global sales ($) |
%
Growth (constant $) |
|
1 |
Antiulcerants |
21.9 |
6% |
+9% |
|
2 |
Cholest.
& Triglyceride Reducers |
21.7 |
5 |
+12 |
|
3 |
Antidepressants |
17.1 |
4 |
+5 |
|
4 |
Antirheumatic
Non-Steroidals |
11.3 |
3 |
+1 |
|
5 |
Calcium
Antagonists, Plain |
9.9 |
3 |
-1 |
|
6 |
Antipsychotics
|
9.5 |
2 |
+19 |
|
7 |
Erythropoietins |
8.1 |
2 |
+18 |
|
8 |
Oral
Antidiabetics |
8.0 |
2 |
+2 |
|
9 |
ACE
Inhibitors, Plain |
7.8 |
2 |
0 |
|
10 |
Cephalosporins
& Combinations |
7.6 |
2 |
-3 |
|
|
|
|
|
|
|
|
Total
Leading 10 ATCs at Level 3 |
$122.8bn |
31% |
+6% |
Source:
IMS World Review 2003
*Note: The figures above reflect 52 weeks of US sales data,
but are compared with 53 weeks of US sales data in 2001, an
adjustment that is made every five years to bring IMS' data
tracking methodology into line with the calendar year. As
a result, 2001 US figures used to calculate the percentage
growth year-over-year (constant dollar) in this table incorporate
five additional days of sales.
Leading
products
In 2002,
the world's top ten best-selling drugs accounted for $44.7
billion in sales, an 11% increase over 2001. Within the
total audited world market, Lipitor was again the top-selling
drug in 2001, with a massive $8.6 billion in sales, up from
$7.0 billion in 2001. Merck & Co's statin, Zocor
(simvastatin), overtook Prilosec as the number two product,
with sales of $6.2 billion. Prilosec's sales dropped 19%
to $5.2 billion, thanks to the generic competition mentioned
above and AstraZeneca's promotion of its follow-up product,
Nexium (esomeprazole).
After
being the top ten drug with the most impressive growth in
2001, Merck & Co's coxib for arthritis, Vioxx (rofecoxib),
dropped out of the top ten in 2002, possibly due to lingering
concerns about its safety. The other coxib, Pharmacia and
Pfizer's Celebrex (celecoxib), fell from
seventh to ninth place.
The
new arrival was Pfizer's SSRI antidepressant Zoloft
(sertraline), which registered 12% growth to reach tenth
position. Lilly's antipsychotic Zyprexa saw the highest
growth, of 21%, and climbed to fourth place from sixth in
2001
Leading
products in 2002 global pharmaceutical sales*
| Rank |
Audited
World Product Sales |
2002
sales ($bn) |
%
Growth (Constant $) |
|
1 |
Lipitor |
8.6 |
+20% |
|
2 |
Zocor |
6.2 |
13 |
|
3 |
Losec/Prilosec
|
5.2 |
-19 |
|
4 |
Zyprexa
|
4.0 |
+21 |
|
5 |
Norvasc |
4.0 |
+6 |
|
6 |
Erypo |
3.8 |
+18 |
|
7 |
Ogastro/Prevacid |
3.6 |
+3 |
|
8 |
Seroxat/Paxil
|
3.3 |
+13 |
|
9 |
Celebrex |
3.1 |
- 1 |
|
10 |
Zoloft |
2.9 |
+12 |
|
|
|
|
|
|
|
Total
10 Leading Products |
$44.7bn |
+11% |
Source:
IMS World Review 2003
*Note: 53 weeks US sales data as above.
IMS
World Review is compiled using IMS' MIDAS™
global analysis system, which captures pharmaceutical activity
from more than 70 countries. Growth in sales is measured
in constant dollars, enabling analyses without the influence
of fluctuating currency exchange rates. Pharmaceutical sales
figures include prescription and certain OTC data, and represent
manufacturer prices. For a full explanation of figures and
collection methods see Data
Value and definitions.
For
further details about IMS World Review 2003,
please contact Paul
Jenner. |
